[1] J-P LAI D L K J T Dalton. Phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a molecular target in lung epithelial wound repair[J]. British Journal of Pharmacology, 2009, 152 8: 1172-1184. DOI:
10.1038/sj.bjp.0707501[2] ANNETTE C. SCHMID. Bisperoxovanadium compounds are potent PTEN inhibitors[J]. FEBS Letters, 2004, 566 1-3: 35-38. DOI:
10.1016/j.febslet.2004.03.102[3] AZUCENA KAKAZU H E P B Guru Sharma. Association of protein tyrosine phosphatases (PTPs)-1B with c-Met receptor and modulation of corneal epithelial wound healing.[J]. Investigative ophthalmology & visual science, 2008: 2927-2935. DOI:
10.1167/iovs.07-0709[4] IAN H BATTY. The control of phosphatidylinositol 3,4-bisphosphate concentrations by activation of the Src homology 2 domain containing inositol polyphosphate 5-phosphatase 2, SHIP2.[J]. Biochemical Journal, 2007, 407 2: 255-266. DOI:
10.1042/bj20070558[5] B I POSNER. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics.[J]. The Journal of Biological Chemistry, 1994, 269 6: 4596-4604.
[6] A P BEVAN. Selective activation of the rat hepatic endosomal insulin receptor kinase. Role for the endosome in insulin signaling.[J]. The Journal of Biological Chemistry, 1995, 270 18: 10784-10791. DOI:
10.1074/jbc.270.18.10784[7] C J BAND. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen).[J]. Molecular endocrinology, 1997, 11 13: 1899-1910. DOI:
10.1210/mend.11.13.0041